MHRA approves adrenaline nasal spray
18/07/2025
The MHRA has been approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
The MHRA has been approved adrenaline (epinephrine) nasal spray (EURneffy) to be used for the emergency treatment of serious allergic reactions, known as anaphylaxis.
As we enter the second half of 2025, Brevia Health has collected and analysed data on parliamentary discussions surrounding the leading diseases in the UK.
The Government published its 10-Year Health Plan for England, Fit for the Future, on Thursday 3 July 2025.
In June 2025, dementia and Alzheimer’s disease took centre stage with a surge in parliamentary interest aligned with national awareness campaigns.
As part of his new responsibilities, he will advise ministers and help drive forward the Government’s vision for health and social care.
In March 2025, data from our Tracker highlighted an awareness month that had a notable impact in the UK Parliament. Mentions of brain tumours by MPs saw a significant uptick.
